750,000 Shares in Drugs Made In America Acquisition Corp. $DMAA Bought by Mercuria Capital Strategies LLC

Mercuria Capital Strategies LLC bought a new position in shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 750,000 shares of the company’s stock, valued at approximately $7,511,000. Drugs Made In America Acquisition accounts for about 6.2% of Mercuria Capital Strategies LLC’s portfolio, making the stock its 6th biggest holding. Mercuria Capital Strategies LLC owned about 2.57% of Drugs Made In America Acquisition at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Wolverine Asset Management LLC increased its position in Drugs Made In America Acquisition by 4.7% during the fourth quarter. Wolverine Asset Management LLC now owns 1,307,468 shares of the company’s stock worth $13,564,000 after acquiring an additional 58,340 shares during the period. JPMorgan Chase & Co. bought a new stake in Drugs Made In America Acquisition in the 3rd quarter valued at $1,024,000. Quarry LP bought a new stake in Drugs Made In America Acquisition in the 3rd quarter valued at $161,000. Clear Street Group Inc. bought a new stake in Drugs Made In America Acquisition in the 3rd quarter valued at $2,152,000. Finally, Bulldog Investors LLP increased its holdings in Drugs Made In America Acquisition by 78.5% in the 3rd quarter. Bulldog Investors LLP now owns 130,264 shares of the company’s stock valued at $1,338,000 after buying an additional 57,300 shares during the period.

Drugs Made In America Acquisition Price Performance

Shares of Drugs Made In America Acquisition stock opened at $10.61 on Friday. The company’s fifty day moving average price is $10.56 and its two-hundred day moving average price is $10.46. Drugs Made In America Acquisition Corp. has a 52-week low of $10.15 and a 52-week high of $10.62.

Drugs Made In America Acquisition (NASDAQ:DMAA) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.06 earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Drugs Made In America Acquisition in a report on Friday, May 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition Company Profile

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.